chevron_leftBack
As of 24 April 2025, OneSource Specialty Pharma Ltd. has a market cap of $2.04B USD, ranking #5261 globally and #363 in India. It ranks #475 in the Healthcare sector, and #116 in the Biotechnology industry.
Key Stats
Market Cap
$2.04BUSD
174.49B INR
Enterprise Value
$2.22BUSD
189.52B INR
Revenue (TTM)
$127.98MUSD
10.92B INR
EBITDA (TTM)
$17.54MUSD
1.5B INR
Net Income (TTM)
-$18.36MUSD
-1.57B INR
EBITDA Margin
14%
Profit Margin
-14%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Neeraj Sharma
open_in_new
Employees
525
Founded
2007
Website
onesourcecdmo.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.1% | -1.1% | -5.1% | -12% | -12% | -12% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ONESOURCE
OneSource Specialty Pharma Ltd
ISIN: INE013P01021
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.56K INR | |
|
544292
(ONESOURCE)
OneSource Specialty Pharma Ltd
ISIN: INE013P01021
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.58K INR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About OneSource Specialty Pharma Ltd.
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India and internationally. The company provides end-to-end CDMO services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. OneSource Specialty Pharma Limited was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. The company was incorporated in 2007 and is based in Bengaluru, India.
